Lumigan in Austria: prescription, pharmacy and pricing
Lumigan (Bimatoprost) is available in Austria under the regulatory framework of BASG (Federal Office for Safety in Health Care). This page summarises how the medication is prescribed and dispensed locally, what insurance or the public system cover, and which options exist for legally and safely accessing Lumigan 0.01%, 0.03%.
- Regulator
- BASG (Federal Office for Safety in Health Care)
- Currency
- EUR
- Active ingredients
- Bimatoprost
- Available dosages
- 0.01%, 0.03%
Prescription status in Austria
Austria's medication categories follow EU rules: rezeptpflichtig (Rx, prescription-only) and rezeptfrei (OTC). The statutory health insurance (Sozialversicherung) covers the bulk of prescription costs after a small per-prescription fee (Rezeptgebühr). Lumigan contains the active ingredient Bimatoprost, in the Eye Care and Ophthalmic Treatments class, and its classification in Austria follows the standard rules of BASG (Federal Office for Safety in Health Care).
Pharmacy dispensing
Austrian Apotheken are well-distributed and bound to strict opening-hour rotation rules; on-call pharmacies (Bereitschaftsdienst) cover nights and holidays. Pharmacist-led consultation is a core part of dispensing, similar to the German system. The pharmacist is the most reliable local source of information on stock, authorised substitutions (generic vs brand) and specific precautions for Lumigan at the available strengths (0.01%, 0.03%).
Online and tele-prescribing access
Online OTC sales are permitted in Austria via BASG-registered pharmacies, identifiable by the EU common logo. Online prescription dispensing is more limited and follows the same legislation as in-person dispensing; cross-border purchase within the EU is regulated. Buying Lumigan from unauthorised sellers or without local verification exposes the user to counterfeit medication and unmonitored use of Bimatoprost.
When Lumigan is prescribed
Lumigan is approved in adults for the reduction of elevated intraocular pressure in patients with chronic open-angle glaucoma or ocular hypertension.
Pricing and availability in EUR
Retail pricing in Austria depends on the strength (0.01%, 0.03%), whether the original brand or an authorised generic is dispensed, and insurance or public-system coverage. The difference between brand and generic is usually the most meaningful economic lever for ongoing use. Comparing prices at two or more locally authorised pharmacies before first refill is recommended.
Frequently asked questions
Do I need a prescription for Lumigan in Austria? ▾
Austria's medication categories follow EU rules: rezeptpflichtig (Rx, prescription-only) and rezeptfrei (OTC). The statutory health insurance (Sozialversicherung) covers the bulk of prescription costs after a small per-prescription fee (Rezeptgebühr). In practice, Lumigan follows the status of its active ingredient Bimatoprost in the regulatory system of BASG (Federal Office for Safety in Health Care).
Is generic Lumigan available in Austria? ▾
Authorised generics of Bimatoprost are typically available in Austria at a lower cost than branded Lumigan, with bioequivalence required by BASG (Federal Office for Safety in Health Care). Substitution is handled by the pharmacist under local equivalence rules.
How much does Lumigan cost in EUR? ▾
Prices in EUR vary by pharmacy and by strength (0.01%, 0.03%). Authorised generics of Bimatoprost are usually substantially cheaper than the brand and are the typical economic reference point for ongoing use in Austria.
Lumigan in other countries
- the United StatesFDA (Food and Drug Administration)
- the United KingdomMHRA (Medicines and Healthcare products Regulatory Agency)
- SpainAEMPS (Agencia Española de Medicamentos y Productos Sanitarios)
- MexicoCOFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios)
- ArgentinaANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica)
- GermanyBfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)
- FranceANSM (Agence nationale de sécurité du médicament et des produits de santé)
- ItalyAIFA (Agenzia Italiana del Farmaco)
- BrazilANVISA (Agência Nacional de Vigilância Sanitária)
- CanadaHealth Canada
- South KoreaMFDS (Ministry of Food and Drug Safety)
- JapanPMDA (Pharmaceuticals and Medical Devices Agency)
- SwitzerlandSwissmedic (Swiss Agency for Therapeutic Products)
- AustraliaTGA (Therapeutic Goods Administration)
- ColombiaInvima (National Food and Drug Surveillance Institute)
- ChileISP (Instituto de Salud Pública de Chile, Public Health Institute)
The information on this website is provided for reference and educational purposes only. It does not replace consultation with a qualified healthcare professional.